News
- Author:
- Ted Bosworth
Publish date: June 15, 2022
The novel NK3 receptor–inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.
News
- Author:
- Ted Bosworth
Publish date: June 14, 2022
A history of prediabetes is predictor of MI independent of any other risk factor, suggesting that screening efforts should increase.
News
- Author:
- Ted Bosworth
Publish date: June 12, 2022
By lowering testosterone levels without untoward hypogonadism, early data show that once-daily contraceptive pills for men could be feasible.
News
- Author:
- Ted Bosworth
Publish date: May 31, 2022
The test detects unstable gene promotors, which are the epigenetic markers for gene expression.
News
- Author:
- Ted Bosworth
Publish date: May 17, 2022
One problem with the new study was the lack of discussion about antibiotic prophylaxis.
News
- Author:
- Ted Bosworth
Publish date: May 16, 2022
“We have not had good-quality studies with the use of modern vibrators.”
News
- Author:
- Ted Bosworth
Publish date: April 25, 2022
On top of statin therapy, icosapent ethyl provides mortality reductions in patients with prior MI.
News
- Author:
- Ted Bosworth
Publish date: April 14, 2022
In a head-to-head comparison in the FLAVOUR trial, IVUS- and FFR-guided PCI produced similar outcomes but had differing strengths.
News
- Author:
- Ted Bosworth
Publish date: April 12, 2022
A transcatheter aortic valve – CoreValve Evolut – is associated for first time with less deterioration than surgical repair at 5 years.
News
- Author:
- Ted Bosworth
Publish date: April 6, 2022
Prompt extraction for implantable device infections is guideline recommended but not often performed.
News
- Author:
- Ted Bosworth
Publish date: April 4, 2022
‘Go early and go low’ is an expert’s response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobuma...
News
- Author:
- Ted Bosworth
Publish date: April 3, 2022
A quality of life subanalysis suggests PCI with fractional flow reserve might be preferred over CABG by at least some patients.
News
- Author:
- Ted Bosworth
Publish date: April 2, 2022
In the CHAP trial, treatment of mild hypertension during pregnancy lowered the risk of adverse maternal and fetal outcomes.
News
- Author:
- Ted Bosworth
Publish date: April 1, 2022
There are many advantages to suppressing disease activity “as soon as possible” after diagnosis, Dr. Erin Wei pointed out.
News
- Author:
- Ted Bosworth
Publish date: March 31, 2022
“There are no serious adverse consequences from these cutaneous reactions,” said Dr. Esther Freeman.
